# Remedee Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/remedee-labs

- Industry: Medical Devices & Equipment
- Headquarters: Saint-Martin, France
- Website: www.remedeelabs.com
- Total disclosed funding: $17M
- Latest round: Series B (May 24, 2022)
- Investors on record: 10

## About

Based in France, Remedee Labs SA specializes in innovative medical devices that alleviate chronic pain and enhance well-being through advanced neuromodulation technology.Founded in 2016 by David Crouzier and Michael Foerster, Remedee Labs SA is headquartered in Saint-Martin, France. The company focuses on developing non-pharmacological solutions for chronic pain management. It has successfully raised EUR 10.050 mn in a SERIES B funding round on December 6, 2022, with notable investors including Banque Hottinguer and Bpifrance. Overall, the company has completed four deals, achieving a current valuation of EUR 45.219 mn.Remedee Labs specializes in innovative, non-pharmacological medical devices designed to alleviate chronic pain and enhance overall well-being. Their flagship product, the Remedee bracelet, utilizes advanced millimeter-wave neuromodulation technology to stimulate the secretion of endorphins, the body's natural painkillers. This device is clinically validated and aims to address various conditions, particularly osteoarthritis and fibromyalgia, by modulating the central nervous system's activity to reduce pain intensity and improve associated symptoms like sleep and fatigue. The company has introduced two primary solutions: Novi Rem™, tailored for patients suffering from osteoarthritis, and Fibro Rem™, specifically designed for fibromyalgia sufferers. These products are marketed in France and have been clinically validated by studies confirming their effectiveness in enhancing patients' quality of life.In 2021, Remedee Labs reported a revenue of EUR 242,867.40. The company generates revenue through the sale of its medical devices, notably the Novi Rem™ and Fibro Rem™, marketed directly to consumers as well as healthcare providers. The business model is structured around direct-to-consumer sales, leveraging partnerships with healthcare professionals to promote the effectiveness of their products. Customers may purchase the bracelets as part of a subscription service that includes ongoing support via the my Remedee™ application, which offers personalized monitoring and integrated services to enhance the management of chronic pain.Remedee Labs plans to leverage its most recent funding to enhance its product offerings and expand its market reach. The company is working on upcoming product launches aimed at improving patient outcomes in chronic pain management. Additionally, Remedee Labs aims to enter new markets beyond France, targeting European and potential international regions by 2025. The investment received from Generali France will support these initiatives and facilitate the development of further innovative solutions.

## Funding rounds

- Series B, May 24, 2022, $11M — Bpifrance, Caisse d'Epargne Rhône-Alpes, Generali France, Habert Dassault Finance, Banque Hottinguer, Banque Populaire du Rwanda, HCVC
- Series A, Jun 3, 2019, $5.8M — Partech Partners, Habert Dassault Finance, HCVC, C4 Ventures, Supernova Invest

## Investors

- Partech Partners (https://capitalatlas.ai/funds/partech-partners) — Series A
- Habert Dassault Finance (https://capitalatlas.ai/funds/habert-dassault-finance) — Series A, Series B
- HCVC (https://capitalatlas.ai/funds/hcvc) — Series A, Series B
- C4 Ventures (https://capitalatlas.ai/funds/c4-ventures) — Series A
- Supernova Invest (https://capitalatlas.ai/funds/supernova-invest) — Series A
- Bpifrance — Series B
- Caisse d'Epargne Rhône-Alpes — Series B
- Generali France — Series B
- Banque Hottinguer — Series B
- Banque Populaire du Rwanda — Series B